Comparison of the Removal of Uremic Toxins With Medium Cut-off and Super High-flux Vitamin E-coated Dialyzers (E-FLUX)
End Stage Renal Disease (ESRD)
About this trial
This is an interventional other trial for End Stage Renal Disease (ESRD) focused on measuring super high-flux hemodialysis, medium cut-off hemodialysis, beta2-microglobulin
Eligibility Criteria
Inclusion Criteria: Signed informed consent Age ≥ 18 years Patients established on HF-HD trice weekly four hour-sessions for at least 3 months Exclusion Criteria: Malabsorption syndrome, active malignant disease or other critical illnesses and any ongoing condition that may interfere with inflammatory parameters (baseline C-Reactive Protein >40 mg/l) Pregnant or breast feeding women Any uncontrolled medical condition, psychiatric disorder or biological abnormality that might interfere with subject's participation or ability to sign an informed consent. Significant residual kidney function as defined by an urine output > 500 mL.
Sites / Locations
- CHU de PoitiersRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
SHFVE-HD group
MCO-HD group
Hemodialysis sessions using the VieX™ (Polysulfone, surface area: 2.1 m², sterilization gamma, ultrafiltration coefficient: 104.3 ml/h/mmHg, Asahi Kasei Medical, Japan).
Hemodialysis sessions using the Theranova 500™ (Baxter healthcare Corporation Deerfield, USA; surface area 2 m², ultrafiltration coefficient: 59 ml/h/mmHg).